https://scholars.lib.ntu.edu.tw/handle/123456789/194504
Title: | Immunogenicity and Reactogenicity of a Reduced-Antigen-Content Diphtheria -Tetanus-Acellular Pertussis Vaccine in Healthy Taiwanese Children and Adolescents | Authors: | HUANG, LI-MIN CHANG, LUAN-YIN LU, CHUN-YI HUANG, FU-YUAN LIN, TZOU-YIEN LEE, CHIN-YUN |
Keywords: | Reduced-antigen-content dTpa vaccine;Bordetella pertussis;Taiwan;Booster vaccination;Adolescents | Issue Date: | 2005 | Journal Volume: | v.37 | Journal Issue: | n.6 | Start page/Pages: | - | Source: | JOURNAL OF ADOLESCENT HEALTH | Abstract: | PURPOSE: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix , GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. METHODS: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme - linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. RESULTS: A total of 180 subjects were recruited . The vaccine response rates to the pertussis antigens ranged between 89.0 -100%. There were no serious adverse events reported during the study period. CONCLUSIONS: The results of this study suggest that Boostrix may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/88697 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.